These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23480615)

  • 1. Fenofibrate and the kidney: an overview.
    Kostapanos MS; Florentin M; Elisaf MS
    Eur J Clin Invest; 2013 May; 43(5):522-31. PubMed ID: 23480615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate, homocysteine and renal function.
    Foucher C; Brugère L; Ansquer JC
    Curr Vasc Pharmacol; 2010 Sep; 8(5):589-603. PubMed ID: 20507276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate: altered renal function.
    Prescrire Int; 2011 Jun; 20(117):154-5. PubMed ID: 21682015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.
    Ansquer JC; Dalton RN; Caussé E; Crimet D; Le Malicot K; Foucher C
    Am J Kidney Dis; 2008 Jun; 51(6):904-13. PubMed ID: 18501783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate-associated nephrotoxicity: a review of current evidence.
    Attridge RL; Frei CR; Ryan L; Koeller J; Linn WD
    Am J Health Syst Pharm; 2013 Jul; 70(14):1219-25. PubMed ID: 23820458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum creatinine levels associated with fenofibrate therapy.
    McQuade CR; Griego J; Anderson J; Pai AB
    Am J Health Syst Pharm; 2008 Jan; 65(2):138-41. PubMed ID: 18192258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.
    Mychaleckyj JC; Craven T; Nayak U; Buse J; Crouse JR; Elam M; Kirchner K; Lorber D; Marcovina S; Sivitz W; Sperl-Hillen J; Bonds DE; Ginsberg HN
    Diabetes Care; 2012 May; 35(5):1008-14. PubMed ID: 22432114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
    Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
    Hottelart C; El Esper N; Rose F; Achard JM; Fournier A
    Nephron; 2002; 92(3):536-41. PubMed ID: 12372935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
    Attridge RL; Linn WD; Ryan L; Koeller J; Frei CR
    J Clin Lipidol; 2012; 6(1):19-26. PubMed ID: 22264570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fenofibrate therapy on renal function in primary gout patients.
    Li X; Sun W; Lu J; He Y; Chen Y; Ren W; Cui L; Liu Z; Wang C; Wang X; Ma L; Cheng X; Han L; Li H; Zhang H; Yuan X; Ji X; Ji A; Merriman TR; Li C
    Rheumatology (Oxford); 2021 Nov; 60(11):5020-5027. PubMed ID: 33704429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
    Rashid ST; Salman M; Agarwal S; Hamilton G
    Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia.
    Salgueiro G; Beltrán LM; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):181-4. PubMed ID: 24940667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and predictors of ACE inhibitor discontinuation subsequent to elevated serum creatinine: a retrospective cohort study.
    Jackevicius CA; Wong J; Aroustamian I; Gee M; Mody FV
    BMJ Open; 2014; 4(8):e005181. PubMed ID: 25232564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.
    Ovcharenko E; Hansen MK; Goltsman I; Abu-Saleh N; Abassi Z; Walsh K; Miele G; Feuerstein GZ; Winaver J
    Nephron Physiol; 2010; 115(3):p21-30. PubMed ID: 20460939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).
    Baggio B; Budakovic A; Perissinotto E; Maggi S; Cantaro S; Enzi G; Grigoletto F;
    Nephrol Dial Transplant; 2005 Jan; 20(1):114-23. PubMed ID: 15572387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
    Ting RD; Keech AC; Drury PL; Donoghoe MW; Hedley J; Jenkins AJ; Davis TM; Lehto S; Celermajer D; Simes RJ; Rajamani K; Stanton K;
    Diabetes Care; 2012 Feb; 35(2):218-25. PubMed ID: 22210576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Letter to the editor by X. Roblin et al., Influence of hypolipemic treatment on homocysteinemia].
    Thomas C
    Rev Med Interne; 2003 May; 24(5):335-6; author reply 336. PubMed ID: 12763184
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrates and renal function.
    Gajdos M; Dzúrik R
    Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
    [No Abstract]   [Full Text] [Related]  

  • 20. Estimated creatinine clearance instead of plasma creatinine level as prognostic test for postoperative renal function in patients undergoing coronary artery bypass surgery.
    Noyez L; Plesiewicz I; Verheugt FW
    Eur J Cardiothorac Surg; 2006 Apr; 29(4):461-5. PubMed ID: 16483789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.